胺碘酮治疗冠心病非急性心肌梗死患者室性心律失常的疗效观察

目的观察胺碘酮治疗冠心病非急性心肌梗死患者室性心律失常的疗效及安全性。方法150例冠心病非急性心肌梗死合并室性心律失常患者,均接受冠心病正规治疗,其中76例同时口服胺碘酮片(胺碘酮组),74例口服普罗帕酮片(普罗帕酮组),疗程8周。疗程开始及结束时均行24h动态心电图及12导联心电图等检查。结果两组患者用药后24h室性早搏、短阵室性心动过速的发作次数均明显减少,胺碘酮组的疗效高于普罗帕酮组(P<0.05),但有4例出现严重副作用。结论胺碘酮对冠心病非急性心肌梗死患者并室性心律失常有很好的治疗作用且疗效优于普罗帕酮,但有一定副作用。

Effect of amiodarone on ventricular arrhythmias in coronary heart diseases with non acute myocardial infarction

Objective To investigate the effect and safety of amiodarone on ventricular arrhythmias(VAs) in patients with non acute myocardial infarction(NAMI) in coronary heart diseases (CHD). Methods 150 patients of NAMI in CHD with VAs accepted the standard therapy of CHD. Among them, 76 patients were treated with amiodarone (amiodarone group) and 74 patients were treated with propafenone(propafenone group). Results In both groups, the occurrence of ventricular arrhythmias were reduced markedly. There was a better effect in amiodarone group than in propafenone group(P<0.05),and there were serious side effects accurred to 4 patients in amiodarone group. Conclusion There is obvious therapeutic efficacy of amiodarone on NAMI in CHD with Vas, and amiodarone is better than propafenone but it has some side effects.